|
1 Indications And Usage Limited Population: Arikayce ® Is Indicated In Adults, Who Have Limited Or No Alternative Treatment Options, For The Treatment Of Mycobacterium Avium Complex (Mac) Lung Disease As Part Of A Combination Antibacterial Drug Regimen In Patients Who Do Not Achieve Negative Sputum Cultures After A Minimum Of 6 Consecutive Months Of A Multidrug Background Regimen Therapy. As Only Limited Clinical Safety And Effectiveness Data For Arikayce Are Currently Available, Reserve Arikayce For Use In Adults Who Have Limited Or No Alternative Treatment Options . This Drug Is Indicated For Use In A Limited And Specific Population Of Patients. This Indication Is Approved Under Accelerated Approval Based On Achieving Sputum Culture Conversion (Defined As 3 Consecutive Negative Monthly Sputum Cultures) By Month 6. Clinical Benefit Has Not Yet Been Established [See Clinical Studies (14) ] . Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials . Limited Population: Arikayce Is An Aminoglycoside Antibacterial Indicated In Adults Who Have Limited Or No Alternative Treatment Options, For The Treatment Of Mycobacterium Avium Complex (Mac) Lung Disease As Part Of A Combination Antibacterial Drug Regimen In Patients Who Do Not Achieve Negative Sputum Cultures After A Minimum Of 6 Consecutive Months Of A Multidrug Background Regimen Therapy. As Only Limited Clinical Safety And Effectiveness Data For Arikayce Are Currently Available, Reserve Arikayce For Use In Adults Who Have Limited Or No Alternative Treatment Options. This Drug Is Indicated For Use In A Limited And Specific Population Of Patients. ( 1 ) This Indication Is Approved Under Accelerated Approval Based On Achieving Sputum Culture Conversion (Defined As 3 Consecutive Negative Monthly Sputum Cultures) By Month 6. Clinical Benefit Has Not Yet Been Established. ( 1 ) Limitation Of Use: Arikayce Has Only Been Studied In Patients With Refractory Mac Lung Disease Defined As Patients Who Did Not Achieve Negative Sputum Cultures After A Minimum Of 6 Consecutive Months Of A Multidrug Background Regimen Therapy. The Use Of Arikayce Is Not Recommended For Patients With Non-Refractory Mac Lung Disease. Limitation Of Use : Arikayce Has Only Been Studied In Patients With Refractory Mac Lung Disease Defined As Patients Who Did Not Achieve Negative Sputum Cultures After A Minimum Of 6 Consecutive Months Of A Multidrug Background Regimen Therapy. The Use Of Arikayce Is Not Recommended For Patients With Non-Refractory Mac Lung Disease.
|